Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells
- University of Birmingham, United Kingdom
- UiT The Arctic University of Norway, Norway
- University of Lübeck, Germany
- University Medical Center Groningen, Netherlands
- University Hospital Frankfurt, Germany
Abstract
Acute myeloid leukaemia (AML) cells interact and modulate components of their surrounding microenvironment into their own benefit. Stromal cells have been shown to support AML survival and progression through various mechanisms. Nonetheless, whether AML cells could establish beneficial metabolic interactions with stromal cells is underexplored. By using a combination of human AML cell lines and AML patient samples together with mouse stromal cells and a MLL-AF9 mouse model, here we identify a novel metabolic crosstalk between AML and stromal cells where AML cells prompt stromal cells to secrete acetate for their own consumption to feed the tricarboxylic acid cycle (TCA) and lipid biosynthesis. By performing transcriptome analysis and tracer-based metabolic NMR analysis, we observe that stromal cells present a higher rate of glycolysis when co-cultured with AML cells. We also find that acetate in stromal cells is derived from pyruvate via chemical conversion under the influence of reactive oxygen species (ROS) following ROS transfer from AML to stromal cells via gap junctions. Overall, we present a unique metabolic communication between AML and stromal cells and propose two different molecular targets, ACSS2 and gap junctions, that could potentially be exploited for adjuvant therapy.
Data availability
RNA-seq data has been deposited in GEO under accession number GSE163478.All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for all figures.Information about AML patient samples obtained from Martini Hospital (UMCG) (Netherlands) and University Hospital Birmingham NHS Foundation Trust, University of Birmingham (UK) have been provided in supplementary Table 1.Source of mice used can be found in Material and methods.
Article and author information
Author details
Grigorios Papatzikas
Jan Jacob Schuringa
Funding
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Nuria Vilaplana-Lopera
- Grigorios Papatzikas
- Alan Cunnigham
- Ayşegüll Erdem
European Commission (HaemMetabolome [EC-675790])
- Jean-Baptiste Cazier
European Commission (HaemMetabolome [EC-675790])
- Jan Jacob Schuringa
European Commission (HaemMetabolome [EC-675790])
- Ulrich Günther
European Commission (HaemMetabolome [EC-675790])
- Paloma Garcia
European Commission (HaemMetabolome [EC-675790)
- Frank Schnütgen
- Jean-Baptiste Cazier
- Jan Jacob Schuringa
- Ulrich Günther
- Paloma Garcia
Deutsche Forschungsgemeinschaft (SFB815,TP A10)
- Frank Schnütgen
Wellcome Trust (208400/Z/17/Z)
- Ulrich Günther
Helse Nord RHF (2014/5668)
- Lorena Arranz
University of Birmingham (67262-DIF Post-Covid Support Fund)
- Paloma Garcia
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Grigorios Papatzikas
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Alan Cunnigham
Horizon 2020 Framework Programme (H2020-MSCA-ITN-2015-675790)
- Ayşegüll Erdem
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Cristina Lo Celso, Imperial College London, United Kingdom
Ethics
Animal experimentation: Animal experiments were conducted with the ethical approval of the Norwegian Food and Safety Authority under project number 19472, with a particular focus on reduction and refinement. Animals were housed under specific opportunistic and pathogen free environment at the Animal Facility of the University of Oslo, Norway. The animals were euthanized by CO2 and absence of reflexes was confirmed before necropsy.
Human subjects: AML and PBMC primary specimens' procedures were obtained in accordance with the Declaration of Helsinki at the University Medical Center Groningen, approved by the UMCG Medical Ethical Committee or at the University Hospital Birmingham NHS Foundation Trust, approved by the West Midlands - Solihull Research Ethics Committee (10/H1206//58).
Version history
- Preprint posted: January 21, 2021 (view preprint)
- Received: November 26, 2021
- Accepted: September 1, 2022
- Accepted Manuscript published: September 2, 2022 (version 1)
- Accepted Manuscript updated: September 7, 2022 (version 2)
- Version of Record published: September 15, 2022 (version 3)
- Version of Record updated: September 29, 2022 (version 4)
Copyright
© 2022, Vilaplana-Lopera et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,244
- views
-
- 491
- downloads
-
- 7
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Crosstalk between AML and stromal cells triggers acetate secretion through the metabolic rewiring of stromal cells
eLife 11:e75908.
https://doi.org/10.7554/eLife.75908
Further reading
-
- Biochemistry and Chemical Biology
- Microbiology and Infectious Disease
To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.
-
- Biochemistry and Chemical Biology
Phosphoinositide 3-kinase (PI3K) beta (PI3Kβ) is functionally unique in the ability to integrate signals derived from receptor tyrosine kinases (RTKs), G-protein coupled receptors, and Rho-family GTPases. The mechanism by which PI3Kβ prioritizes interactions with various membrane-tethered signaling inputs, however, remains unclear. Previous experiments did not determine whether interactions with membrane-tethered proteins primarily control PI3Kβ localization versus directly modulate lipid kinase activity. To address this gap in our knowledge, we established an assay to directly visualize how three distinct protein interactions regulate PI3Kβ when presented to the kinase in a biologically relevant configuration on supported lipid bilayers. Using single molecule Total Internal Reflection Fluorescence (TIRF) Microscopy, we determined the mechanism controlling PI3Kβ membrane localization, prioritization of signaling inputs, and lipid kinase activation. We find that auto-inhibited PI3Kβ prioritizes interactions with RTK-derived tyrosine phosphorylated (pY) peptides before engaging either GβGγ or Rac1(GTP). Although pY peptides strongly localize PI3Kβ to membranes, stimulation of lipid kinase activity is modest. In the presence of either pY/GβGγ or pY/Rac1(GTP), PI3Kβ activity is dramatically enhanced beyond what can be explained by simply increasing membrane localization. Instead, PI3Kβ is synergistically activated by pY/GβGγ and pY/Rac1 (GTP) through a mechanism consistent with allosteric regulation.
